Federal U.S. health officials said Friday they are considering new standards that would require tobacco companies to reduce nicotine levels in cigarettes to nonaddictive levels, as part of a sweeping review of industry regulations.
Continue Reading Below
Shares of major tobacco companies tumbled on the move by the Federal Drug Administration. Marlboro maker Altria Group Inc. fell 10%, while British American Tobacco PLC, maker of Camel cigarettes, tumbled 8.5%.
The agency said it was adopting a harm-reduction strategy that seeks to balance regulation of existing products and encourage development of "new products that may be less dangerous than cigarettes." Among the issues it will examine is the role of menthol and other flavors in tobacco products.
The FDA will consider an exemption for premium cigars, and will allow more time for makers of reduced-risk products to submit product applications under the agency's recently implemented rules, FDA Commissioner Scott Gottlieb said in a press conference.
Mr. Gottlieb said the agency would look at regulation to "render cigarettes minimally addictive."
"Cigarettes will likely remain incredibly toxic," he said. "We may be able to reach a day when the most harmful products will no longer be capable of addicting our kids."
Continue Reading Below
Altria, British American Tobacco and Philip Morris International didn't immediately respond to requests to comment.
A spokesman for Imperial Brands said, "We note the FDA's announcement relating to its strategic direction but until the eventual development of specific proposals, it's too early to understand the practical implications."
Mr. Gottlieb said the FDA's new approach would consider "a continuum of risk for nicotine delivery," from combustible products such as cigarettes to nicotine-replacement therapies such as nicotine patches and gums. Cigarette smoke, he said, not nicotine, is what causes cancer, heart disease and lung disease.
"The problem is not just nicotine, the problem is the delivery mechanism, " Mr. Gottlieb said. Cigarettes kill 480,000 people in the U.S. each year, according to the Centers for Disease Control and Prevention.
Some tobacco analysts were skeptical. Citigroup analyst Adam Spielman said he didn't believe the FDA will be able to lower nicotine to nonaddictive levels because defining that level will be difficult, it would be hard to make cigarettes with a very low level of nicotine and there would be huge political opposition.
"We don't believe the proposal to reduce nicotine in cigarettes dramatically is practical," said Mr. Spielman, adding that Friday's tobacco stock drops are unjustified.
E-cigarettes and vaping devices that were on the market in August 2016 won't be subject to review until 2021 or 2022, depending on the type of product. The agency also will consider the potential impact of a black market for cigarettes.
Some antismoking advocates and public health officials been urging the FDA and CDC to provide the public with information on the relative risks of tobacco products. Until now, U.S. health officials have stuck with an abstinence-only message to the public.
The FDA's shift comes as the agency considers whether to approve new marketing claims for new heat-not-burn devices, smokeless tobacco and other products. In April, Reynolds American, which was recently acquired by BAT, submitted applications to market six styles of Camel Snus tobacco pouches as being less harmful than cigarettes. Philip Morris also has an application pending for a new device that heats tobacco instead of burning it.
Write to Jennifer Maloney at email@example.com
(END) Dow Jones Newswires
July 28, 2017 12:17 ET (16:17 GMT)